The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 27, 2015

Filed:

Apr. 05, 2013
Applicants:

Koji Kawakami, Kyoto, JP;

Stella Pharma Corporation, Osaka-shi, JP;

Inventors:

Koji Kawakami, Kyoto, JP;

Masayuki Kohno, Kyoto, JP;

Tomohisa Horibe, Kyoto, JP;

Oumi Nakajima, Kyoto, JP;

Mari Haramoto, Kyoto, JP;

Liying Yang, Kyoto, JP;

Assignees:

Other;

Stella Pharma Corporation, Osaka, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); C07K 5/00 (2006.01); C07K 7/00 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01); C12P 21/06 (2006.01); C12N 1/20 (2006.01); C12N 15/00 (2006.01); C12N 5/00 (2006.01); C12N 5/02 (2006.01); C12N 15/74 (2006.01); A61P 35/00 (2006.01); C07H 21/04 (2006.01); C07K 7/08 (2006.01); A61K 47/48 (2006.01); C07K 14/475 (2006.01); C07K 14/485 (2006.01); C07K 14/54 (2006.01); C07K 7/06 (2006.01); C07K 14/00 (2006.01);
U.S. Cl.
CPC ...
C07K 7/08 (2013.01); A61K 47/48276 (2013.01); C07K 14/475 (2013.01); C07K 14/485 (2013.01); C07K 14/54 (2013.01); C07K 7/06 (2013.01); C07K 14/001 (2013.01); C07K 2319/33 (2013.01); C07K 2310/55 (2013.01);
Abstract

It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.


Find Patent Forward Citations

Loading…